Pediatric Guidelines

AU Comment: Australian national guidance Although some Australian states and territories have individual perinatal guidelines, Australian National guidance is primarily available via the ASID Management of Perinatal Infections guidelines, which are in turn based on the BHIVA guidelines for the management of HIV in pregnancy and postpartum. The Australian Commentary on the DHHS guidelines will include references to both …

ARV Management of Newborns with Perinatal HIV Exposure or HIV Infection Read More »

AU Comment: Adolescents living with HIV ASHM provides some guidance for clinicians in Australasia managing adolescents living with HIV and their transition to adult services, refer to HIV Management Guidelines, chapter: HIV infection in adolescents transitioning to adult care. Panel’s Recommendations All adolescents with HIV should receive maximally suppressive antiretroviral (ARV) therapy; this is urgent for …

Special Considerations for ART Use in Adolescents with HIV Read More »

Panel’s Recommendations Strategies to maximize adherence should be discussed before and/or at initiation of antiretroviral therapy (ART) and before changing regimens (AIII). Adherence to therapy must be assessed and promoted at each visit, and strategies to maintain and/or improve adherence must be continually explored (AIII). In addition to viral load monitoring, at least one other method of …

Adherence to ART in Children and Adolescents with HIV Read More »

Panel’s Recommendations In children with HIV who have severe or life-threatening toxicity (e.g., a hypersensitivity reaction), all antiretroviral (ARV) drugs should be stopped immediately (AIII). Once symptoms of toxicity have resolved, ARV therapy should be resumed with substitution of a different ARV drug or drugs for the offending agent(s) (AII*). When modifying ARV therapy because of toxicity or …

Management of Medication Toxicity or Intolerance Read More »

AU Comment: Raltegravir granules Raltegravir granules are NOT currently available in Australia. AU Comment: Age and weight based criteria Age and weight based criteria may differ in Australia. AU Comment: Maraviroc Maraviroc is NOT licensed for children in Australia. AU Comment: ibalizumab ibalizumab is NOT currently licensed for children in Australia. AU Comment: Travel with ART A supportive letter may be required to …

Management of Children Receiving ART Read More »

Panel’s Recommendations Outside the context of clinical trials, structured interruptions of antiretroviral therapy are not recommended for children (AII). Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized …

ART Interruption in Children with HIV Read More »

The Australian Commentary has been written and reviewed by members of the ASHM HIV Paediatric Guidelines Committee. The members of the Committee and other contributors who contributed to the Australian Commentary from 2020-2023 are listed below: Name Position Adam Bartlett (chair) Research Fellow, The Kirby Institute Paediatric Infectious Diseases Physician, Sydney Children’s Hospital Brett Richie …

Committee Read More »